螺内酯对肾移植受者肾功能的影响:SPIREN随机安慰剂对照试验
SPIREN试验为随机、安慰剂对照、双盲研究,纳入188例肾移植受者,随机接受螺内酯或安慰剂治疗3年。螺内酯使实测GFR急性下降(最多较安慰剂低7.6 ml/min,95%CI −10.9至−4.3),但随后肾功能曲线保持稳定,1年后降低24小时蛋白尿,对间质纤维化进展无显著影响。结论:在标准治疗基础上加用螺内酯3年未改善肾功能、长期蛋白尿或间质纤维化。
要点
- 螺内酯对肾移植患者安全,但会引起GFR急性下降,之后保持稳定。
- 螺内酯治疗1年后降低24小时蛋白尿,但对长期蛋白尿无改善。
- 螺内酯对方案活检中间质纤维化进展无显著影响。
核心结论
- 在肾移植受者标准治疗基础上加用螺内酯3年,未改善肾功能、长期蛋白尿或间质纤维化。
研究设计与样本
- 随机、安慰剂对照、双盲临床试验,纳入188例 prevalent 肾移植患者,随机接受螺内酯或安慰剂治疗3年。
- 每年测定实测GFR、24小时蛋白尿和血压;基线和2年后收集肾脏活检(n=48),纤维化采用定量立体学和Banff分类评估。
- 主要终点为实测GFR变化;次要终点包括24小时蛋白尿、移植肾纤维化和心血管事件。
主要发现
- 螺内酯组实测GFR较安慰剂组下降(最多−7.6 ml/min,95%CI −10.9至−4.3),与移植后时间和血压无关,但随时间肾功能曲线无影响。
- 螺内酯治疗1年后降低24小时蛋白尿。
- 螺内酯对间质纤维化的发展无显著影响。
- 两组基线特征可比,仅螺内酯组移植物稍老。
临床怎么用
- 肾移植受者使用螺内酯需注意GFR急性下降,但后续肾功能保持稳定。
- 螺内酯可用于降低肾移植患者短期蛋白尿,但不应期望改善长期肾功能或纤维化。
局限性
- 活检亚组样本量较小(n=48)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Spironolactone is safe for kidney transplant patients. Spironolactone reduces kidney function by an acute effect, whereafter it remains stable. Spironolactone does not affect the progression of interstitial fibrosis in protocol biopsies. BACKGROUND: Long-term kidney allograft survival is hampered by progressive interstitial fibrosis and tubular atrophy. The SPIREN trial tested the hypothesis that the mineralocorticoid receptor antagonist spironolactone stabilizes kidney function and attenuates glomerular barrier injury in kidney transplant patients treated with calcineurin inhibitors. METHODS: We conducted a randomized, placebo-controlled, double-blind clinical trial including 188 prevalent kidney transplant patients. Patients were randomized to spironolactone or placebo for 3 years. GFR was measured along with proteinuria and kidney fibrosis. The primary end point was change in measured GFR. Secondary outcomes were 24-hour proteinuria, kidney allograft fibrosis, and cardiovascular events. Measured GFRs, 24-hour proteinuria, and BP were determined yearly. Kidney biopsies were collected at baseline and after 2 years (n=48). Fibrosis was evaluated by quantitative stereology and classified according to Banff. RESULTS: The groups were comparable at baseline except for slightly older allografts in the spironolactone group. Spironolactone reduced measured GFRs (up to –7.6 [95% confidence interval, −10.9 to −4.3] ml/min compared with placebo) independently of time since transplantation and BP with no effect on the kidney function curve over time and reduced 24-hour proteinuria after 1 year. There was no significant effect of spironolactone on the development of interstitial fibrosis. CONCLUSIONS: Spironolactone added to standard therapy for 3 years in kidney transplant patients did not improve kidney function, long-term proteinuria, or interstitial fibrosis. CLINICAL TRIAL REGISTRATION NUMBER: NCT01602861.
引用
- Mortensen LA, Jespersen B, Helligsoe ASL, et al. Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients (the SPIREN trial): A Randomized Placebo-Controlled Clinical Trial. Clin J Am Soc Nephrol. 2024. PMID: 38416033. doi:10.2215/CJN.0000000000000439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。